Recombinant CD28 antibody

Catalog No. ABIN7487691

The Mouse Monoclonal anti-CD28 antibody has been validated for FACS and ELISA. It is suitable to detect CD28 in samples from Human.

Quick Overview for Recombinant CD28 antibody (ABIN7487691)

Target: CD28

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD28 antibody is un-conjugated

Application: Flow Cytometry (FACS), ELISA

Clone: 15E8

Product Details anti-CD28 Antibody

Purpose: Anti-CD28 [15E8], Mouse IgG1, kappa

Specificity: This antibody binds human CD28, which is found on a sub-population of T cells and activated B cells. The antibody does not react with B cells, granulocytes or monocytes. CD28 is involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival.

Characteristics:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Immunogen: The original mouse antibody was generated by immunizing mice with human T lymphocytes.

Isotype: IgG1 kappa

Application Details

Application Notes: This antibody works independently of TcR/CD3 and activation of protein kinase C (PKC) for activation of T cells and nehances cytokine secretion (PMID: 1647959). This antibody is capable of stimulating T cells in combination with either murine OKT3 antibody or CDR-mutated OKT3 Fab variants. It was found that cross-linking of specific tumor antigens with the T-cell-associated CD3 and CD28 antigens can increase IL-2 secretion, proliferation and antigen-specific cytotoxicity in resting T cells. This cross-linking can be achieved effectively by bispecific monoclonal antibodies (BiMAb) with specificity for both the tumor antigen and CD3 or CD28 antigen. A combination of bispecific antibodies BiMAb OKT3/HRS-3 with reactivity against both CD3 and Hodgkin's-lymphoma-associated CD30 antigen and BiMAb 15E8/HRS-3 with reactivity to both CD28 and CD30 antigen was able to activate resting T cells, represented by Jurkat cells (CD3+/CD28+) to produce IL-2 (PMID: 7686889). This antibody was also used in another study wherein the combined use of two CD3 x CD19 plus CD28 x CD22 bispecific antibodies induced optimal interleukin 2 secretion by Jurkat T-cell acute lymphocytic leukemia cells in the presence of target B-cells (PMID: 7689932). This antibody also provides a co-stimulatory signal to T cells. The scFv fragment of this antibody induced proliferation of peripheral blood mononuclear cells in the presence of anti-CD3 or anti-CD2 mAb and enhanced anti-tumor activity of anti-MUC1xanti-CD3 bispecific antibody when tested with lymphokine-activated killer cells with T cell phenotype (PMID: 10913626). The humanzied version of this antibody is available on request.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for CD28

Target: CD28

Alternative Name: CD28

Background: T-cell-specific surface glycoprotein CD28, TP44

UniProt: P10747

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response